Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT06130124 Recruiting - Clinical trials for Essential Hypertension

S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement

Start date: February 22, 2023
Phase:
Study type: Observational

Evaluate the ratio(%) of patients whose blood pressure measured at 6 months from the baseline was confirmed to be within the target blood pressure range according to the 2022 hypertension treatment guidelines for essential hypertension patients who received the study drug.

NCT ID: NCT06121518 Completed - Clinical trials for Essential Hypertension

Clinical Trial to Evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy

Start date: July 31, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the Efficacy and Safety of D064 and D702 Combination Therapy Versus D064 or D702 Monotherapy in Essential Hypertension Patients

NCT ID: NCT06116357 Not yet recruiting - Clinical trials for Primary Hypertension

The Safety and Efficacy of Carotid Body Modulation Therapy in Hypertensive Patients by External Ultrasonic Micro-bubble

Start date: December 1, 2023
Phase: N/A
Study type: Interventional

The investigators intend to find a noninvasive method for CB modulation therapy and find a simple and convenient indicator for assessing CB activity. This study was designed to evaluate the safety and efficacy of carotid body modulation therapy in hypertensive patients by external ultrasonic micro-bubble and also identify the association between CB volume and CB activity.

NCT ID: NCT06093932 Recruiting - Clinical trials for Hypertension,Essential

Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial

ESCIHP
Start date: June 2024
Phase: Phase 4
Study type: Interventional

The purpose of this study is: 1. To evaluate the efficacy of Songling Xuemaikang Capsules(SLXMKC) with grade 1 hypertension. 2. To reveal the potiential effects of SLXMKC on vascular function and structure of patients with grade 1 hypertension. 3. To explore the underlying mechanisms of the therapeutic effects of SLXMKC on the intervention of grade 1 hypertension.

NCT ID: NCT06091176 Not yet recruiting - Clinical trials for Essential Hypertension

Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension

Start date: November 1, 2024
Phase: N/A
Study type: Interventional

This is a multicenter, randomized, single-blind, parallel-group study to evaluate the efficacy and safety of Amicomed® compared with Usual Care (UC) over a 24-week treatment period in subjects with essential hypertension (mean, home based systolic blood pressure (SBP) ≥ 140 and/or diastolic blood pressure DBP ≥ 90 mm Hg on Day 1).

NCT ID: NCT06090617 Recruiting - Hypertension Clinical Trials

Water and Electrolytes Content in HYpertension (WHYSKI) in the SKIn

WHYSKI
Start date: January 1, 2021
Phase:
Study type: Observational

WHYSKI is a prospective within-patient observational clinical study designed to test the hypothesis that alterations of Na+, K+, water, and the lympho-angiogenetic transcription factor Tonicity Enhancing Binding Protein (TonEBP) mRNA take place in the interstitium of the skin compartment of patients with arterial hypertension due to primary aldosteronism in whom hypertension can be surgically cured.

NCT ID: NCT06084065 Recruiting - Hypertension Clinical Trials

Feasibility and Effectiveness of a Ring-type Blood Pressure Measurement Device

Start date: July 13, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to evaluate the feasibility and effectiveness of a ring-type blood pressure measurement device compared to a 24-hour ambulatory blood pressure monitoring device in patients with hypertension or suspected hypertension. The main question it aims to answer is whether the 24-hour blood pressure measurement accuracy of the ring-type blood pressure monitor is similar to that of the 24-hour ambulatory blood pressure monitor. To participate, subjects must wear a ring blood pressure monitor and an ambulatory blood pressure monitor simultaneously for 24 hours.

NCT ID: NCT06059638 Recruiting - Hypertension Clinical Trials

BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT

BACKBEAT
Start date: December 27, 2023
Phase: N/A
Study type: Interventional

A prospective, multinational, randomized, double-blind, clinical trial evaluating the safety and effectiveness of a novel atrioventricular interval modulation (AVIM) algorithm downloaded into a previously implanted dual-chamber Medtronic Astra/Azure DR MRI IPG.

NCT ID: NCT06052748 Recruiting - Clinical trials for Hypertension,Essential

A Study to Evaluate the Efficacy and Safety of AD-223

Start date: February 15, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AD-223

NCT ID: NCT06049862 Recruiting - Clinical trials for Primary Hypertension

The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial

"MaRiTensi"
Start date: October 11, 2023
Phase: N/A
Study type: Interventional

This study aims to know the effectiveness of "MaRiTensi" in improving knowledge, motivation, efficacy, self-care and blood pressure control for hypertension patients. This study hypothesizes that MaRiTensi effectively increases the knowledge, motivation, self-efficacy and self-care of hypertensive patients and reduces blood pressure in the intervention group compared to the control group. Respondent recruitment is as follows: 1. The respondent candidate will be identified based on data on record medical 2. Appropriate respondent candidates' criteria inclusion and exclusion contacted for given informed consent 3. Prospective respondents who are willing to participate and fulfill the criteria for pressure blood moment measurement will request signed consent 4. Respondents fill in the basic data and recapitulate by the assistant researcher 5. Done randomization for allocation of group interventions and group control 6. Respondents given envelope closed (using sequentially numbered, opaque sealed envelopes (SNOSE) method ) 7. Respondents' group intervention was given maintenance by Hospital or health center standard-added intervention using MaRiTensi by conditions; meanwhile, group control was provided care by Hospital or health center standards.